Science 37 appoints Paul von Autenried to its Board of Directors
October 05 2022 - 4:15PM
Science 37® Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial
Operating System™, today announced the appointment of seasoned
industry and technology executive Paul von Autenried to its Board
of Directors.
Mr. von Autenried spent 26 years in leadership roles at Bristol
Myers Squibb Company, including most recently having served as
Chief Information Officer and an Executive Committee member from
2011 to 2022.
“I’ve long admired Science 37 and its unique operating system to
enable sponsors to accelerate clinical research,” said Mr. von
Autenried. “I look forward to working with the board and management
to support its evolution and next phase of growth.”
“I’m delighted to welcome Paul to our Board of Directors,” said
David Coman, Chief Executive Officer of Science 37. “His
extraordinarily deep industry and technology expertise will provide
immense value to Science 37, as we continue to accelerate clinical
research and enable access to patients without geographic
limitations.”
As Mr. von Autenried joins the Board of Directors replacing
Adam Goulburn.
“I would like to take this opportunity to provide a heartfelt
‘thank you’ to Adam for his valuable contribution to Science 37,”
said Mr. Coman. “As a long-time member of our board, Adam was
instrumental in helping us to achieve our extraordinary growth and
was a catalyst to our public offering in 2021. We wish him all the
best in his future endeavors.”
About Science 37Science 37 Holdings, Inc.’s
(Nasdaq: SNCE) mission is to enable universal access to clinical
research—making it easier for patients and providers to participate
from anywhere and helping to accelerate the development of
treatments that impact patient lives. As a pioneer of decentralized
clinical trials, the Science 37 l Operating System (OS) supports
today’s more agile clinical research designs with its full stack,
end-to-end technology platform and centralized networks of patient
communities, telemedicine investigators, mobile nurses, remote
coordinators, provider communities, and data and devices.
Configurable to enable almost any study type, the Science 37 OS
enables up to 21x faster enrollment, 28% better retention and 3x
more diverse patient population with industry-leading workflow
orchestration, evidence generation and data harmonization. For more
information, visit https://www.science37.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains certain
forward-looking statements within the meaning of the federal
securities laws, including statements regarding the products
offered by Science 37, its sales pipeline and the markets in which
it operates. These forward-looking statements generally are
identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result” and similar expressions.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to: (i) the ability to maintain
the listing of Science 37’s securities on Nasdaq, (ii) volatility
in the price of Science 37’s securities due to a variety of
factors, including changes in the competitive and highly regulated
industries in which Science 37 operates, variations in performance
across competitors, changes in laws and regulations affecting
Science 37’s business and changes in its capital structure, (iii)
the ability to implement business plans, forecasts, and other
expectations, and to identify and realize additional opportunities,
(iv) the risk that Science 37 may never achieve or sustain
profitability, (v) the risk that Science 37 will need to raise
additional capital to execute its business plan, which may not be
available on acceptable terms or at all, and (vi) the potential
adverse effects of the ongoing global COVID-19 pandemic. The
foregoing list of factors is not exhaustive. You should carefully
consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of our Annual
Report on Form 10-K for the fiscal year ended December 31, 2021
filed with the U.S. Securities and Exchange Commission (the “SEC”)
on March 22, 2022 and in our other documents filed by Science 37
from time to time with the SEC. These filings identify and address
other important risks and uncertainties that could cause actual
events and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Science 37
assumes no obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise, except as required by law. Science 37
does not give any assurance that Science 37 will achieve its
expectations.
MEDIA INQUIRIES:Drew BustosScience
37PR@science37.com
INVESTOR RELATIONS:Caroline PaulScience 37 //
GilmartinInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jul 2023 to Jul 2024